--- title: 'Senior Internal Auditor - SOX Compliance at Tonix Pharmaceuticals' canonical: 'https://feeny.ai/job/senior-internal-auditor-sox-compliance-tonix-pharmaceuticals-berkeley-heights-5s2s64ygvz1q' type: 'job' last_seen: '2026-09-23' --- # Senior Internal Auditor - SOX Compliance at Tonix Pharmaceuticals - **Company:** Tonix Pharmaceuticals - **Location:** Berkeley Heights, NJ - **Compensation:** $80k–$110k - **Posted:** 2026-09-16 - **Last confirmed live:** 2026-09-23 - **Apply:** https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4405955009 ## Job description Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit [www.tonixpharma.com](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9p5FBvlzG2u-9NzVEDdUgRNdl57Mw08p4h9XviYYnbwVJ-X_DNEOeN4RdGA64IhTnk9R4lQWNXhq0g8TrvoRTCZSpqmowBapMZCbqP_sxm0%3D&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987080441%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=WrmW8ZuY9XRYJZM0BMPu3thoab5uVHnt9SqBNHIoDuU%3D&reserved=0) and follow the Company on [LinkedIn](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DbldblPUeLBo2VtrimIDsthVk4RaPH1sCjnDw18J2Q9UGKOYpi7kKsd6NuJ4rb7a1ocGevguAt4l_8t8TE5rfCP1YmSBTJO1HR9Uo9KAv_DEwtbEkJhm1CdLRAEbAUNB-&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987109283%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=dHRzyv5dfKFOhCroh809txjNcJOjNrBSQRyfSgHaIu8%3D&reserved=0) and [X](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D0NgIEJjy96AytWlfgCqgqVv5cOeUVkGOTFS78koSy22XXOczOtXjxSorNUcN-uDTk4CYVQkJndgCk6o2RQBlKQ%3D%3D&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987130654%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=frLcoK5ETOWzJq9lmvkirCS8HaHc2WCX%2Fg4ESMSdLgk%3D&reserved=0). *Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Summary Tonix Pharma is seeking a Senior Internal Auditor to support its Sarbanes-Oxley (SOX) compliance program. This position will be responsible for evaluating the design and operating effectiveness of internal controls over financial reporting and supporting the company’s ongoing compliance with Section 404 of the Sarbanes-Oxley Act. The Senior Internal Auditor will work closely with Finance, Accounting, Information Technology, Legal, Compliance, business process owners, external auditors, and third-party service providers. The successful candidate will have strong SOX and internal-controls experience, sound audit judgment, and an understanding of the financial-reporting risks present in the biotechnology or pharmaceutical industry. ## Key Responsibilities - Conduct process walkthroughs with control owners to understand financial-reporting risks, control activities, systems, and supporting documentation. - Prepare and maintain process narratives, flowcharts, risk and control matrices, testing procedures, and other SOX documentation. - Evaluate the design and implementation of key controls over financial reporting. - Evaluate the completeness and accuracy of information used in the performance of controls. - Monitor changes to business processes, personnel, systems, transactions, and organizational structure that may affect SOX scope or control design. - Execute the company’s annual SOX compliance plan in accordance with established timelines, testing standards, and documentation requirements. - Perform testing across all Financial Process (Order to Cash, Procure to Pay, Financial Reporting and Consolidation, Inventory, Fixed Assets et al.) - Document testing procedures, evidence, conclusions, and review notes in accordance with internal standards. - Identify control deficiencies and assess their severity, potential financial-reporting impact, root cause, and compensating controls. - Communicate testing results and control observations clearly and constructively to process owners and management. - Partner with control owners to develop practical remediation plans and monitor corrective actions through completion. - Perform remediation and roll-forward testing to confirm that control improvements have been implemented and are operating effectively. - Support SOX readiness and other significant business changes. - Coordinate with external auditors and respond to documentation or testing requests. - Track SOX testing progress, open deficiencies, remediation status, and program metrics for management reporting. Required Qualifications - Bachelor’s degree in accounting, finance, business administration, information systems, or a related field. - At least 4–6 years of experience in internal audit, external audit, SOX compliance, public accounting, or internal controls. - Demonstrated experience performing SOX walkthroughs and design and operating-effectiveness testing. - Strong understanding of internal controls over financial reporting and the COSO framework. - Experience documenting processes, risks, controls, testing procedures, and audit conclusions. - Ability to identify, analyze, and clearly communicate control deficiencies. - Strong analytical, organizational, project-management, and problem-solving skills. - Excellent written and verbal communication skills. - Ability to work independently, manage multiple deadlines, and collaborate effectively across functions. - Proficiency in Microsoft Excel, Word, PowerPoint, and Visio or similar process-mapping tools. ## Preferred Qualifications - Experience in the biotechnology, pharmaceutical, medical-device, healthcare, or life-sciences industry. - CPA, CIA, CISA, or progress toward a relevant professional certification. - Big Four or other public-accounting experience. - Experience supporting the SOX program of a publicly traded company. - Experience with ERP systems such as NetSuite and Coupa. - Experience supporting SOX compliance during ERP implementations other significant organizational changes. ## Key Competencies - Internal-control and SOX expertise - Professional skepticism and sound judgment - Accuracy and attention to detail - Clear and constructive communication - Accountability and follow-through - Cross-functional collaboration - Project and deadline management - Continuous-improvement mindset - Integrity and confidentiality Salary Range $80,000—$110,000 USD *Please note that Tonix does not offer sponsorship for this role. Recruitment & Staffing Agencies Tonix does not accept agency resumes unless contacted directly by internal Tonix Talent Acquisition. Please do not forward resumes to Tonix employees or any other company location; Tonix is not responsible for any fees related to unsolicited resumes. ## Compensation & Benefits Tonix provides a comprehensive compensation and benefits package which includes: - Medical, Dental & Vision Insurance, Basic and Voluntary Life and AD&D Insurance, Short- and Long-Term Disability Insurance, Flexible Spending Accounts, Health Savings Account, and Employee Assistance Programs - Pet Insurance - Retirement Savings 401k with company match and annual discretionary stock options - Generous Paid Time Off, Sick Time, & Paid Holidays - Career Development and Training Tonix provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, genetics, or any other characteristic protected by law.  In addition to federal law requirements, Tonix complies with applicable state and local laws governing nondiscrimination in employment.  This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfers, leaves of absence, compensation, and training.  Tonix expressly prohibits any form of workplace harassment based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, genetic, information, disability, veteran status, or any other characteristic protected by law. ## About Tonix Pharmaceuticals ## Company Overview - **One-liner**: A fully-integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. - **Entity Type**: Public (NASDAQ: TNXP) - **Headquarters**: Berkeley Heights, New Jersey, United States (as indicated by zip code 07922 on the investor relations page) [ir.tonixpharma.com](https://ir.tonixpharma.com/) - **Founded**: Not publicly available from provided sources - **Founders**: Not publicly available from provided sources ## Core Business - **Primary industry/industries**: Biotechnology / Pharmaceuticals (therapeutics) - **Target customers**: B2B – physicians (rheumatology, primary care, pain management, neurology), hospitals, specialty distributors, and patients through prescription-based access. - **Mission or purpose statement**: “We listen, we develop, we deliver – so that patients feel seen, heard, and empowered to live fully again.” [tonixpharma.com](https://www.tonixpharma.com/) ## Products & Services - **TONMYA® (cyclobenzaprine HCl sublingual tablets)**: Approved in the U.S. (August 2025) and launched in November 2025 for the treatment of fibromyalgia in adults – the first new medicine for fibromyalgia in over 15 years. Non-opioid, centrally acting analgesic designed for bedtime dosing. [tonixpharma.com](https://www.tonixpharma.com/) - **Zembrace® SymTouch® (sumatriptan injection)**: FDA-approved prescription product for the treatment of acute migraine. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **Tosymra® (sumatriptan nasal spray)**: FDA-approved prescription product for acute migraine. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-102 SL (cyclobenzaprine HCl sublingual tablets)**: Investigational for Major Depressive Disorder (Phase 2 planned mid-2026) and Acute Stress Disorder/Reaction (Phase 2 enrolling, OASIS study at UNC funded by DoD). [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-4800 (anti-OspA monoclonal antibody)**: Seasonal prevention of Lyme disease – Phase 2 field study planned first half 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-1500 (humanized anti-CD40L mAb)**: Phase 2-ready for prevention of kidney transplant rejection (investigator-initiated study expected mid-2026) and treatment of autoimmune diseases. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-1300 (double-mutant cocaine esterase)**: Phase 2 for cocaine intoxication; FDA Breakthrough Therapy designation. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-2900 (intranasal oxytocin + magnesium)**: For Prader-Willi Syndrome – Orphan Drug and Rare Pediatric Disease designations; Phase 2 planned Q1 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-801 (horsepox live virus vaccine)**: Preclinical – mpox/smallpox protection; Phase 1 expected in 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-4200 (small molecule anti-CD45)**: Broad-spectrum antiviral for biodefense; preclinical, supported by up to $34M DoD contract. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-1700 (TFF2-albumin fusion)**: Preclinical for gastric/colorectal cancer in combination with PD-1 blockade (in-licensed from Columbia University). [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) - **TNX-4900 (Sigma-1 receptor antagonist)**: Preclinical non-opioid analgesic for neuropathic pain. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf) ## Market Standing - **Valuation/Market Cap**: Not publicly available from provided sources (public stock; market cap fluctuates) - **Key Metric**: Annual Revenue – Not disclosed in provided sources (commercial launch of TONMYA began November 2025; earlier revenue from Zembrace/Tosymra). Total funding rounds not applicable for public company. R&D expenditures detailed in 10-K but not extracted. - **Notable Investors/Partners**: Almac Pharma Services (commercial supply for TONMYA) [10-K]; U.S. Department of Defense (DTRA contract up to $34M for TNX-4200) [10-K]; University of North Carolina (OASIS study for TNX-102 SL) [10-K]; Columbia University (TNX-1700 in-license) [10-K]. - **Growth Signals**: First FDA approval and launch of internally developed drug TONMYA (Nov 2025); expanding commercial payer coverage (second commercial agreement covering ~52M U.S. lives) [tonixpharma.com]; multiple Phase 2 programs advancing; ownership of two manufacturing facilities (RDC in Frederick, MD and ADC in Dartmouth, MA) [10-K]. ## Competitive Advantages - **First-mover in fibromyalgia**: TONMYA is the first new FDA-approved treatment for fibromyalgia in 15+ years, with a proprietary sublingual formulation that offers differentiated bioavailability and tolerability. - **Broad, diversified pipeline**: Covers CNS, immunology, infectious disease, and rare disease – reducing single-program risk and providing multiple shots on goal. - **In-house manufacturing**: Owned R&D Center (Frederick, MD) with BSL-2/3 capability and an Advanced Development Center (Dartmouth, MA) for live-virus vaccine and biologics production (currently decommissioned but ready for reactivation) [10-K]. - **Non-opioid focus**: All analgesic candidates (TONMYA, TNX-4900) are non-opioid, aligning with regulatory and societal trends away from opioids. - **Government partnerships**: DTRA contract for biodefense work (TNX-4200) provides non-dilutive funding and mission relevance. ## Strategic Focus - **Grow TONMYA**: Expand commercial coverage, physician adoption, and patient access for fibromyalgia treatment. - **Advance pipeline**: Initiate or complete Phase 2 studies for TNX-102 SL (MDD, ASD), TNX-4800 (Lyme), TNX-1500 (transplant rejection), TNX-1300 (cocaine intoxication), TNX-2900 (Prader-Willi), and move TNX-801 (mpox/smallpox vaccine) into Phase 1. - **Pursue strategic business development**: In-licensing, partnerships, and potential acquisitions to augment pipeline and commercial portfolio [10-K]. ## Why Work Here - **Culture**: The company emphasizes a collaborative, inclusive environment where every voice is heard. Mission-driven focus on “listening to patients’ lived experiences” and developing therapies for underserved, complex conditions. [tonixpharma.com/careers](https://www.tonixpharma.com/careers/) - **Work model**: Information on remote/hybrid policy not publicly available. Office and lab facilities in Berkeley Heights, NJ (HQ), Frederick, MD (R&D Center), and Dartmouth, MA (Advanced Development Center). - **Team & growth**: Opportunity to work on first-in-class drug launches (TONMYA) and cutting-edge science across multiple therapeutic areas. The company is at a pivotal stage transitioning from pure R&D to a commercial organization, offering varied career pathways. - **Benefits**: Equal opportunity employer; does not offer visa sponsorship for open positions. [tonixpharma.com/careers](https://www.tonixpharma.com/careers/) - **Notable perks/engineering culture**: Not detailed, but the science-driven environment with in-house manufacturing and government-funded biodefense work may appeal to researchers and engineers in pharma. ## Sources 1. [tonixpharma.com](https://www.tonixpharma.com/) – Company homepage, mission, product info, lat _…truncated._ ## Other roles at Tonix Pharmaceuticals - [​​Senior Director, Regulatory Affairs – Infectious Disease​](https://feeny.ai/job/senior-director-regulatory-affairs-infectious-disease-tonix-pharmaceuticals-jyjj3xn080t8) — Berkeley Heights NJ OR Frederick, MD - [Senior Clinical Project Manager](https://feeny.ai/job/senior-clinical-project-manager-tonix-pharmaceuticals-berkeley-heights-v6zs7ea8q265) — Berkeley Heights, NJ - [Executive Assistant to the Chief Executive Officer](https://feeny.ai/job/executive-assistant-to-the-chief-executive-officer-tonix-pharmaceuticals-q21ne61fzfhr) — Berkeley Heights NJ OR New York, NY - [Regional Sales Director - California](https://feeny.ai/job/regional-sales-director-california-tonix-pharmaceuticals-california-8thn8v1c8d4r) — California - [Associate Medical Director, Clinical Development](https://feeny.ai/job/associate-medical-director-clinical-development-tonix-pharmaceuticals-berkeley-pa6mx85qwvws) — Berkeley Heights, NJ - [Manager, SEC Reporting](https://feeny.ai/job/manager-sec-reporting-tonix-pharmaceuticals-berkeley-heights-x4szc7r8yxkq) — Berkeley Heights, NJ - [Senior Associate, Supplier Quality](https://feeny.ai/job/senior-associate-supplier-quality-tonix-pharmaceuticals-north-dartmouth-ma-or-bfw25b7mxm0z) — North Dartmouth MA OR Berkeley Height, NJ - [Scientist II, In-Vitro & Nonclinical Assay Development](https://feeny.ai/job/scientist-ii-in-vitro-nonclinical-assay-development-tonix-pharmaceuticals-xfw3p1cqhsr3) — Frederick, MD - [Senior Manager, Information Security](https://feeny.ai/job/senior-manager-information-security-tonix-pharmaceuticals-frederick-md-or-062sk1rtyd2t) — Frederick MD OR Berkeley Heights, NJ - [Senior Specialist, Corporate Communications](https://feeny.ai/job/senior-specialist-corporate-communications-tonix-pharmaceuticals-berkeley-0rn9ax1k9r08) — Berkeley Heights NJ OR New York, NY